Top Chinese CRO Increases Clinical Trial Productivity and Drives Innovation Across Asia with Medidata Technology

Medidata (NASDAQ:MDSO), the leading global provider of cloud-based solutions for clinical research in life sciences, today announced that R&G Pharma Studies Co., Ltd. (“R&G”), a leading contract research organization (CRO) in China, has broadened its adoption of the Medidata Clinical Cloud®, becoming the first Chinese customer to use Medidata’s clinical trial management technology Medidata CTMS®. By leveraging the configurable, cloud-based system, R&G is optimizing clinical site management and trial activities for its life sciences customers across the Asia-Pacific (APAC) region-helping to accelerate innovative drug development and the delivery of vital new therapies to patients.

“We are pleased that R&G is further realizing the benefits of the Medidata platform by becoming the first Chinese customer to adopt our flexible, robust clinical trial management solution,” said Edwin Ng, Medidata’s vice president of field operations for APeJ (Asia-Pacific except Japan). “China is a key market in APAC’s expanding clinical trial landscape, and R&G is well positioned to support clinical innovation in the region. By pairing Medidata’s agile, cloud-based technology with R&G’s deep clinical expertise and industry insight, we look forward to fueling better, more strategic research across the region.”

David Wu, CEO and founder of R&G, said: “R&G is dedicated to providing high-quality and efficient research services to a wide range of clients in the life sciences industry, both domestically and abroad. We selected Medidata CTMS for its simple configurations, which allow us to more effectively manage complex trial operations across different study phases and therapeutic areas. With Medidata’s flexible technology, we can now access and provide our clients with important trial information in real time-enabling us to meet important milestones on time without compromising quality.”

Headquartered in Beijing, R&G provides a full range of clinical trial services-including regulatory affairs, clinical monitoring, data management capabilities, biostatistics, pharmacoeconomics, site management organization (SMO) services, and staffing and outsourcing-supporting studies on both a global and domestic scale. The company, which offers unique clinical research expertise in areas such as oncology, cardiovascular, central nervous system and medical devices, has worked with more than 260 Chinese and international clients and collaborated with hundreds of sites.

Since early 2015, R&G has been utilizing Medidata’s industry-leading cloud technology for electronic data capture and management (Medidata Rave®). To further streamline R&D operations and transform its Phase I-IV research programs, R&G is adopting Medidata’s cloud-based CTMS for its advanced site monitoring capabilities, high-quality performance reports and real-time insight into trial activity via its integration with Rave.

“We’re excited to further expand our use of Medidata’s unified platform, extending beyond Rave to incorporate its robust trial management and monitoring capabilities-ultimately helping to streamline workflows for better trial operations and better clinical outcomes,” Wu added.